SHANGHAI, Jan. 9, 2021 / PRNewswire / – VISEN Pharmaceuticals, a biotechnology company specializing in the development and commercialization of innovative endocrine drugs that address the significant unmet needs of patients in Greater China, today announced the closing of a Series B funding of $ 150 million.
The round was led by Sequoia China with participation from OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital and CDG Capital, as well as all existing investors, including Ascendis Pharma A / S , Vivo Capital and Sofinnova Investments. Proceeds from the Series B funding will be used to accelerate the clinical development of the best potential drug candidates in the portfolio and to build a solid foundation for commercialization.
“We appreciate the confidence of our existing shareholders as well as our new investors in our innovative endocrine portfolio and our team, which has solid medical expertise in endocrinology….
News Highlights Finance
- According to the source VISEN Pharmaceuticals Closes $ 150 Million Series B Funding to Accelerate Development and Commercialization of Its Innovative Endocrinology Therapies in Greater China
- Check all news and articles from the Finance news updates.